The influence of steroidotherapy in COPD exacerbation on matrix metalloproteinase MMP-9 level in BAL, induced sputum and serum Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
The effect of inhaled budesonide on MMP-8 and TIMP-1 expression in induced sputum of asthmatic children Source: Eur Respir J 2004; 24: Suppl. 48, 595s Year: 2004
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
Increased levels of hyaluronan in induced sputum from COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 436s Year: 2003
Relationship between sputum level of matrix metallopreteinase (MMP-9)/tissue inhibitor of metalloproteinase (TIMP-1) and methacholine bronchial hyper-reactivity in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005
Decreased levels of myeloperoxidase in induced sputum of COPD patients after oral glucocorticoids treatment Source: Eur Respir J 2002; 20: Suppl. 38, 404s Year: 2002
Imbalance between serum matrix metalloproteinase-9 and its inhibitor is associated with increased airway wall thickness in uncontrolled asthmatics Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation Year: 2010
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases expression in the bronchial secretions of asthmatics and COPD Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002
Increased gelatinase and collagenase activity in induced sputum from COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 179s Year: 2003
Inhibitory effects of budesonide/formoterol on extracellular matrix in TGFß1-stimulated bronchial biopsy fibroblasts from mild asthmatic patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Correlation of serum Matrix metalloproteinase-9 and clinico-functional parameters in COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005
Effect of inhaled budesonide on BAL inflammatory cells and MMP-12 expression in COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Change of induced sputum TNF-a and sTNF-R55,75 levels in patients with acute exacerbations of COPD Source: Annual Congress 2007 - Respiratory pathophysiology Year: 2007
Induced sputum concentrations of mucin in patients with asthma and chronic cough Source: Eur Respir J 2007; 30: Suppl. 51, 61s Year: 2007
Matrix metalloproteinase-9 (MMP-9) elevated in serum, but not in bronchial lavage in lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
Glycosaminoglycans significantly correlate with matrix metalloproteinases during exacerbations of COPD Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015